

Express Mail Label: EL 710 606 310 US
Docket No. JAB-1669

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Raymond A. Stokbroekx et al.
Serial No. : 09/998,975 Art Unit: 1624
Filed : October 19, 2001 Examiner: Truong, Tamthom Ngo
For : ANGIOGENESIS INHIBITING 5-SUBSTITUTED-1,2,4-
THIADIAZOLYL DERIVATIVES

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

AUG 18 2003

INFORMATION DISCLOSURE STATEMENT

OFFICE OF PETITIONS

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action

Express Mail Label: EL 710 606 301 US
Docket No. JAB-1669

after the filing of a request for continued examination under \$1.114,
no additional fee is required.

☐ Please charge Deposit Account No. 10-0750/JAB-
1669/AGK the fee of \$180.00 as set forth in
\$1.17(p).

☐ Copies of each of the references listed on the attached
Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449
are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list
as appropriate], and the likelihood that these
references are available to the Examiner, copies are
not enclosed herewith.

☐ If any of the foregoing publications are not
available to the Examiner, Applicant will endeavor to
supply copies at the Examiner's request.

☐ There are no listed references which are not in the
English language.

☐ The relevance of those listed references which are not in
the English language is as follows:


☐ Attached are copies of search report(s) from corresponding
patent application(s), which are listed on the attached Submission
Under MPEP 609 D.

Express Mail Label: EL 710 606 301 US
Docket No. JAB-1669

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB-1669/AGK. This form is submitted in triplicate.

Respectfully submitted,



Alana G. Kriegsman
Reg. No. 41,747
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1495
DATED: June 18, 2003

Express Mail Label: EL 710 606 310 US
Docket No. JAB-1669

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Raymond A. Stokbroekx et al.
Serial No. : 09/998,975 Art Unit: 1624
Filed : October 19, 2001 Examiner: Truong, Tamthom Ngo
For : ANGIOGENESIS INHIBITING 5-SUBSTITUTED-1,2,4-
THIADIAZOLYL DERIVATIVES

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action

Express Mail Label: EL 710 606 301 US
Docket No. JAB-1669

after the filing of a request for continued examination under \$1.114,
no additional fee is required.

☐ Please charge Deposit Account No. 10-0750/JAB-
1669/AGK the fee of \$180.00 as set forth in
\$1.17(p).

☐ Copies of each of the references listed on the attached
Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449
are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list
as appropriate], and the likelihood that these
references are available to the Examiner, copies are
not enclosed herewith.

☐ If any of the foregoing publications are not
available to the Examiner, Applicant will endeavor to
supply copies at the Examiner's request.

☐ There are no listed references which are not in the
English language.

☐ The relevance of those listed references which are not in
the English language is as follows:

☐ Attached are copies of search report(s) from corresponding
patent application(s), which are listed on the attached Submission
Under MPEP 609 D.

Express Mail Label: EL 710 606 301 US .
Docket No. JAB-1669

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB-1669/AGK. This form is submitted in triplicate.

Respectfully submitted,



Alana G. Kriegsman
Reg. No. 41,747
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1495
DATED: June 18, 2003

Express Mail Label: EL 710 606 310 US
Docket No. JAB-1669



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Raymond A. Stokbroekx et al.
Serial No. : 09/998,975 Art Unit: 1624
Filed : October 19, 2001 Examiner: Truong, Tamthom Ngo
For : ANGIOGENESIS INHIBITING 5-SUBSTITUTED-1,2,4-
THIADIAZOLYL DERIVATIVES

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

AUG 18 2003

INFORMATION DISCLOSURE STATEMENT

OFFICE OF PETITIONS

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action

RECEIVED
JUN 23 2003
TECH CENTER 1624/na

after the filing of a request for continued examination under \$1.114, no additional fee is required.

☐ Please charge Deposit Account No. 10-0750/JAB-1669/AGK the fee of \$180.00 as set forth in \$1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☐ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Express Mail Label: EL 710 606 301 US
Docket No. JAB-1669

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB-1669/AGK. This form is submitted in triplicate.

Respectfully submitted,



Alana G. Kriegsman
Reg. No. 41,747
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1495
DATED: June 18, 2003

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.